Nisa Investment Advisors LLC Sells 8,857 Shares of TransMedics Group, Inc. $TMDX

Nisa Investment Advisors LLC decreased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 50.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,653 shares of the company’s stock after selling 8,857 shares during the quarter. Nisa Investment Advisors LLC’s holdings in TransMedics Group were worth $971,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in shares of TransMedics Group by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock worth $107,845,000 after buying an additional 11,241 shares during the last quarter. Marshall Wace LLP raised its holdings in TransMedics Group by 258.7% during the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after acquiring an additional 394,340 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after purchasing an additional 86,721 shares during the last quarter. Zevenbergen Capital Investments LLC grew its stake in TransMedics Group by 112.7% in the third quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock valued at $29,006,000 after purchasing an additional 136,995 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of TransMedics Group by 5.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 221,276 shares of the company’s stock worth $29,653,000 after purchasing an additional 11,599 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 4,142 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the sale, the director directly owned 2,866 shares in the company, valued at $373,869.70. The trade was a 59.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Anil P. Ranganath sold 3,000 shares of the company’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $2,026,545.10. This represents a 17.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 13,062 shares of company stock valued at $1,797,634. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $143.69 on Friday. The stock has a market cap of $4.91 billion, a PE ratio of 58.17 and a beta of 2.03. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The firm has a 50-day moving average of $130.39 and a 200-day moving average of $122.57. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The firm had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. During the same period in the prior year, the firm earned $0.12 EPS. The business’s revenue was up 32.2% on a year-over-year basis. On average, sell-side analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on TMDX. Zacks Research cut shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Morgan Stanley boosted their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Jefferies Financial Group started coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 target price for the company. Finally, Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research report on Sunday, December 28th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $144.25.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.